Surrozen, Inc./DE (SRZN) stock
Close on Nov 12, 2026Market cap $372.24MP/E –Yield –
Surrozen, Inc./DE saw revenue fall 8.8% to $11.51M over the twelve months to Jun 30, 2026. Free cash flow was -$34.98M. At the latest close the market valued the company at $372.24M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $372.24M
- P/E ratio
- –
- Price to sales
- 32.34
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -9.40%
Fundamentals
- Revenue
- $11.51M
- Net income
- -$332.13M
- EPS, diluted
- -$32.37
- Free cash flow
- -$34.98M
- Book value per share
- -$9.45
- Diluted shares
- 23M
Trading
- Next earnings
- Mar 22, 2027 (estimated, after the close)
- Previous close
- $31.88
- Open
- $32.31
- Day's range
- $30.53 – $32.45
- Volume
- 134,042
- Average volume (20 days)
- 287,504
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.52
- 52-week range
- $12.12 – $37.83
- RSI (14 days)
- 59.7
- Volatility (1 year)
- 135.7%
- Relative volume
- 0.29×
- WACC
- 7.5%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | SRZN | S&P 500 | Difference | SRZN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +27.9% | -2.7% | +30.6 pts | ||
| 3 months | +30.9% | -1.7% | +32.7 pts | ||
| Year to date | +40.1% | +11.9% | +28.2 pts | ||
| 1 year | +144.7% | +12.0% | +132.8 pts | ||
| 3 years | +493.8% | +78.2% | +415.6 pts | +81.1% | +21.2% |
| 5 years | -77.7% | +73.2% | −150.9 pts | -25.9% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Surrozen filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Surrozen
Biological Products, (No Diagnostic Substances)
Surrozen is a biotechnology company that discovers and develops antibody-based therapeutics designed to selectively regulate the Wnt signaling pathway for tissue repair. Its operations center on ophthalmology, targeting diseases such as diabetic macular edema, wet age-related macular degeneration, and uveitic macular edema. The company's lead candidates include SZN-8141, SZN-8143, and SZN-413, which aim to restore retinal vascular integrity and inhibit abnormal blood vessel growth. It also conducts preclinical research programs for corneal endothelial injuries and photoreceptor degeneration. Its therapies target patients suffering from serious ocular disorders, and its clients include corporate partners such as Boehringer Ingelheim International GmbH.
Company profile, executives and historySurrozen stock: common questions
What is Surrozen's stock price?
SRZN closed at $31.67 on Nov 12, 2026, down 0.66% on the day. Over the past 52 weeks it traded between $12.12 and $37.83.
What is Surrozen's market cap?
Surrozen was worth $372.24M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is SRZN's P/E ratio?
Surrozen lost money over fiscal 2025 (diluted EPS -$32.37), so it has no meaningful P/E ratio.
How much revenue does Surrozen make?
Surrozen reported revenue of $11.51M for the twelve months to Jun 30, 2026, down 8.8% from a year earlier.
Does Surrozen pay a dividend?
No. Surrozen has not paid a cash dividend over the last twelve months.
When does Surrozen report earnings next?
Surrozen is expected to report Q4 FY2026 results on Mar 22, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has SRZN stock performed over the past year?
Including dividends, SRZN returned +144.7% over the past year, against +12.0% for the S&P 500.
How many SRZN shares are sold short?
3M shares were sold short at the latest FINRA report, 49.58% of the float, or 8.5 days of average trading volume.
Who are Surrozen's competitors?
Companies most similar to Surrozen by business, industry and size include RLAY, VYGR, LCTX, SGMOQ, ZEOX.
See a number that looks wrong?